{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:03:54Z","timestamp":1789581834362,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurjcn\/zvag198","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:50:17Z","timestamp":1787226617000},"source":"Crossref","is-referenced-by-count":0,"title":["Stubborn stasis in the prevalence of metabolic syndrome: a case for pharmacotherapy-based innovation for cardiovascular health"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6400","authenticated-orcid":false,"given":"Robert M","family":"Gifford","sequence":"first","affiliation":[{"name":"University of Edinburgh School of Neurological and Cardiovascular Sciences, Queen\u2019s Medical Research Institute , Edinburgh EH16 4TJ ,","place":["UK"]},{"name":"Academic Department of Military Medicine, Royal Centre of Defence Medicine , ICT Centre, Vincent Drive, Birmingham B12 2SQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091613363911300_zvag198-B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjcn\/zvag177","article-title":"Estimated global prevalence of metabolic syndrome: a proportional meta-analysis","author":"Chan","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2026091613363911300_zvag198-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S2213-8587(22)00317-5","article-title":"Treating chronic diseases without tackling excess adiposity promotes multimorbidity","volume":"11","author":"Sattar","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091613363911300_zvag198-B3","doi-asserted-by":"crossref","DOI":"10.1111\/obr.12949","article-title":"The challenge of keeping it off, a descriptive systematic review of high-quality, follow-up studies of obesity treatments","volume":"21","author":"Nordmo","year":"2020","journal-title":"Obes Rev"},{"key":"2026091613363911300_zvag198-B4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091613363911300_zvag198-B5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091613363911300_zvag198-B6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026091613363911300_zvag198-B7","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"2026091613363911300_zvag198-B8","author":"Gallup"},{"key":"2026091613363911300_zvag198-B9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(25)00356-0","article-title":"GLP-1 receptor agonists for obesity: eligibility across 99 countries","volume":"14","author":"Yoo","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091613363911300_zvag198-B10","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"key":"2026091613363911300_zvag198-B11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World health organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"2026091613363911300_zvag198-B12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(26)00554-4","article-title":"Making treatment for obesity more equitable","volume":"407","author":"The Lancet","year":"2026","journal-title":"Lancet"}],"container-title":["European Journal of Cardiovascular Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjcn\/advance-article-pdf\/doi\/10.1093\/eurjcn\/zvag198\/71129518\/zvag198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjcn\/advance-article-pdf\/doi\/10.1093\/eurjcn\/zvag198\/71129518\/zvag198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:36:44Z","timestamp":1789580204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjcn\/advance-article\/doi\/10.1093\/eurjcn\/zvag198\/8802469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1093\/eurjcn\/zvag198","relation":{},"ISSN":["1474-5151","1873-1953"],"issn-type":[{"value":"1474-5151","type":"print"},{"value":"1873-1953","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"zvag198"}}